Norgine B.V. enters into exclusive distribution agreement for the commercialisation of PLENVU in China with Beijing Podconley Pharmaceutical Technology & Development Co., Ltd. - Seite 2

www.norgine.com
Follow us @norgine

About PLENVU

PLENVU, Powder for Oral Solution (PEG 3350, Sodium Ascorbate, Sodium Sulfate, Ascorbic Acid, Sodium Chloride, and Potassium Chloride), is indicated in adults for bowel cleansing prior to any procedure requiring a clean bowel. PLENVU, Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/8578/smpc#gref Accessed April 2021.

About Colorectal Cancer and colonoscopy

Colorectal cancer is the second most common cause of cancer-related mortality world-wide.^[3] Colorectal cancer is largely preventable, with early detection being associated with a 90% cure rate.^[4] Colonoscopy is an effective method for colorectal cancer screening and has been shown to reduce both the incidence and mortality of colorectal cancer when applied in the general population. Inadequate pre-colonoscopy bowel cleansing reduces the diagnostic accuracy of colonoscopy, particularly for the detection of smaller lesions and sessile (slightly flattened) polyps. This may result in repeated procedures, thereby potentially increasing patient burden, resource requirement and costs and can possibly delay the initiation of treatment.^[5],[6],[7]

About Norgine

Norgine is a leading European specialist pharmaceutical company that has been bringing transformative medicines to patients for over a century. Our commitment to transforming people's lives drives everything we do and our European experience, fully integrated infrastructure and exceptional partnership approach enables us to quickly apply creative solutions to bring life-changing medicines to patients that they may not otherwise be able to access. Norgine is proud to have helped 22 million patients around the world in 2020 and generated €448 million in net product sales, a growth of 7% over 2019.

Norgine has a direct presence in 12 European countries, as well as Australia and New Zealand. We also have a strong global network of partnerships in non-Norgine markets. We are a flexible and fully integrated pharmaceutical business, with manufacturing (Hengoed, Wales and Dreux, France), third party supply networks and significant product development capabilities, in addition to our sales and marketing infrastructure. This enables us to acquire, develop and commercialise specialist and innovative products that make a real difference to the lives of patients around the world.